ArticleJACC. Case reports2026
A Discovery of Potentially Hereditary Cardiac Angiosarcoma.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac angiosarcomas are rare, often rapidly progressing to malignant tumors with poor prognosis. CASE SUMMARY: We present the case of a 31-year-old man with shortness of breath and cough. Diagnostic work-up revealed an infiltrative right atrial mass with obstruction of flow, and biopsy confirmed primary cardiac angiosarcoma. Family history was notable for cardiac angiosarcoma in his father, diagnosed at age 32. After multidisciplinary tumor board discussion, resection was performed prior to initiation of chemotherapy. The postoperative course was complicated by recurrent pericardial and pleural effusions. After genetic analysis, a POT-1 gene variant of uncertain significance was discovered. DISCUSSION: This case underscores the lack of current screening guidelines for those who are potentially at risk. TAKE-HOME MESSAGES: Early detection of angiosarcomas is vital given rapid tumor progression. Further classification of deleterious mutations for POT1 tumor predisposition can potentially open more patients to extensive screening before the development of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.